Telitacicept FDA Approval Status
Last updated by Melisa Puckey, BPharm on Nov 30, 2023.
FDA Approved: No
Generic name: Telitacicept
Company: RemeGen Biosciences
Treatment for: Rheumatoid Arthritis
Telitacicept is a novel fusion protein for the treatment of autoimmune diseases.
Telitacicept is an investigational novel recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor fusion protein that operates by targeting and neutralizing B lymphocyte stimulator (BLyS) and a proliferating-inducing ligand (APRIL). evaluating its use for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Telitacicept is currently being evaluated for use for autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.
Development timeline for Telitacicept
| Date | Article |
|---|---|
| Nov 15, 2023 | Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.